Optibrium expands operations in North America

Share this on social media:

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, has announced the opening of its US subsidiary, Optibrium Inc. Dr Tamsin Mansley has been promoted to president of the new subsidiary to lead its US-based team and business operations. The opening aims to strengthen the Company’s direct sales, and technical and application support for new and existing US customers, expanding the global presence and customer base of Optibrium’s StarDrop and Augmented Chemistry platforms.

Based in Cambridge, Massachusetts, Optibrium Inc sits in a life sciences network of biotech and pharma companies. The headcount of Optibrium’s US-based team has doubled throughout 2022. The opening of Optibrium’s US business will enable further growth and create additional recruitment opportunities, including business development and application scientist roles.

Tamsin joined Optibrium in 2015 as Head of North American Operations, before also being appointed to Global Head of Application Science in 2021. During her time at Optibrium, Tamsin has significantly grown its US-based team, customer base, and operational capacity. She has over 16 years’ experience in developing and commercialising computational modelling and chemoinformatic software, with previous roles at other key companies in the field, including OpenEye, Dotmatics and Certara. Through working on research and discovery programmes at UCB Research and Eli Lilly, Tamsin developed extensive expertise in medicinal chemistry. She holds a PhD in Organic Chemistry from the University of East Anglia, a BSc in Chemistry, Life Systems and Pharmaceuticals from the University of York and carried out postdoctoral research at the University of Texas.

Dr Tamsin Mansley, President at Optibrium, said: “I am delighted to see our growth celebrated with the opening of Optibrium Inc. – a true reflection of the great work from our US team. The opening is an exciting development that gives Optibrium a stronger foothold in the global drug discovery market and allows us to better support our US-based customers on the ground.”

Dr Matthew Segall, CEO of Optibrium, commented: “Establishing Optibrium Inc. is a major milestone that demonstrates our trajectory towards further growth, and is testament to the hard-work and commitment from Tamsin and her team. It strengthens the global position of our innovative AI platforms and in silico technologies, and I am confident that Optibrium Inc. will accelerate the next phase of our development.”

 

EMBL-EBI training course. Credit: Jeff Dowling

27 January 2022